Orthofix Medical Inc. (OFIX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 36/100 (MEDIUM), 14.1 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 6.25% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Orthofix Medical (OFIX) Stock Sees Fair Value Cut After Analysts Trim Q2 Outlook
- Orthofix Medical Sees Reimbursement Rebound, but Spine Slump Clouds Outlook
- Orthofix (OFIX) Q2 2026 Earnings Call Transcript
- Orthofix Medical Q2 Earnings Call Highlights
- Orthofix Medical (OFIX) Looks Attractive After CMS Reversed Its Reimbursement
- Orthofix Medical (OFIX) Among the Best Small-Cap Growth Stocks To Buy Now
- Orthofix (OFIX) Moves 5.1% Higher: Will This Strength Last?
- Orthofix Medical (OFIX) Stock Sees Split Analyst Revisions After CMS Reimbursement Reset
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Orthofix Medical Inc..
Full OFIX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.